An option fee from potential program acquirer TuHura has enabled Kineta to resume enrolling a Phase I/II study of a VISTA-targeted antibody that the company thinks has best-in-class potential.

Lupin’s CEO highlights market access strategy as a key tool to ensure biosimilars success in the US while being relieved the company didn’t launch a Humira biosimilar. She also mentions Amazon and Mark Cuban have not upset market dynamics for generics in the US and a Lucentis biosimilar is closer to a global launch post Phase III trial success

Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.

BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.